Lundbeck’s Parkinson Drug Foliglurax Latest Flop

Discussion in 'Lundbeck' started by anonymous, Apr 1, 2020 at 8:39 PM.

Tags: Add Tags

  1. anonymous

    anonymous Guest

    Another one bites the dust from our R&D. The migraine drug is being panned by Wall St. as a niche drug because of the competition and its IV admin. Will the $2 billion purchase of Alder prove to be a good move, or a super flop? Will the virus force Lundbeck to drastically reorganize the sales force into something totally different from today (contract or combo of contract/full time)? Will Takeda or Otsuka want to renegotiate their contracts with Lundbeck?

    Who knows, but stay tuned and see what happens.
     
  2. anonymous

    anonymous Guest

    Yep... Par for the course with Lundbeck. And good luck launching an infused drug during a global pandemic. This isn't life saving. No way infusion centers will want pseudo-electivecare in with the oncology patients and home infusion won't be reimbursed for headaches.
     
  3. anonymous

    anonymous Guest

    This is the same complaint we have heard since almost the inception of psych in January 2013. Lundbeck has been a psuedo contract company with Otsuka and Takeda. The sales numbers are pretend. The Vikings have gotten most of their money up front. They dont want much skin in the game so they took cash up front a little piece of the game and then ran a scam on the sales force. The money they got from Otsuka on the epic failure of the Alzheimer drug that ne er got out of trials was banked and a great bargaining chip to get a little piece of Maintena and Brex. These Vikings dont like putting more than a toe in the water. It's a shame all the money has been wasted buying 3rd tier drugs in competitive markets. What happened to unmet medical needs?
     
  4. anonymous

    anonymous Guest

    def contract reps and the other companies know this
     
  5. anonymous

    anonymous Guest

    Vyepti will safe the day...
     
  6. anonymous

    anonymous Guest

    crappy name for a crappy drug with a crappy route of administration.

    Yay Lundbeck!